AstraZeneca revealed it has stopped another phase 3 lung cancer trial in the same period, citing interim findings that its volrustomig program, when combined with chemotherapy, was unlikely to increase survival versus an existing treatment option. The company said the Independent Data Monitoring Committee recommended the pause following a planned data review. The termination adds to a broader pipeline disruption that has affected investor confidence and raises questions about AstraZeneca’s strategy to move beyond checkpoint inhibitor benchmarks in lung cancer. In practical terms, the stoppage means additional time and costs will not be recovered through continued recruitment and longer follow-up. The decision also highlights how oncology development committees weigh survival endpoints and relative efficacy early in phase 3—especially for bispecific approaches meant to compete against established standards. Future communications are likely to address any learnings on patient selection and whether any efficacy signals emerged outside the primary comparison. Taken together with the company’s other contemporaneous clinical interruptions, the two volrustomig-related stops suggest the drug’s clinical profile has not met the bar needed for ongoing phase 3 development.